Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Committee to Propose Basic Policy for Science and Technology
March 11, 2002
-
ARCHIVE BULLETIN
March 11, 2002
-
ARCHIVE IFN Prices to Be Cut by 25%
March 11, 2002
-
ARCHIVE Maruishi: Sales, Profits Up due to Increases in Exports
March 11, 2002
-
ARCHIVE WEBSIITE NEWS
March 11, 2002
-
ARCHIVE NCC Forecasts Survival Rates for Cancer Will Double by 2015
March 11, 2002
-
ARCHIVE Gov't to Formulate Basic Policy for New Healthcare System for Elderly in FY2002
March 11, 2002
-
ARCHIVE Novartis Foundation Provides Support for 53 Researchers
March 11, 2002
-
ARCHIVE Each Drug Firm Has Tie-ups with 18 Others: FTC Survey
March 11, 2002
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
March 11, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF
March 11, 2002
-
ARCHIVE OTS NEWS IN BRIEF
March 11, 2002
-
ARCHIVE GE Information Supply Fee to Be Introduced: Revision -1-
March 4, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
March 4, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
March 4, 2002
-
ARCHIVE NEW PRODUCTS
March 4, 2002
-
ARCHIVE CORPORATE ROUNDUP NEWS IN BRIEF
March 4, 2002
-
ARCHIVE China Attracts Growing Number of Companies
March 4, 2002
-
ARCHIVE GE Information Supply Fee to Be Introduced: Revision -3-
March 4, 2002
-
ARCHIVE NanoCarrier Ties Up with Amarin to Develop New DDS Technology
March 4, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…